Tyrosine kinase inhibitorFDA-approvedFirst-line
Crizotinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 60% of patients achieved an objective response, with median progression-free survival of approximately 10.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Crizotinib May Help Reduce Pulmonary Fibrosis | Lung Cancer | animal-study | — | Source → |
| Crizotinib's Effectiveness in Lung Cancer Treatment | Lung Cancer | meta-analysis | Compared with chemotherapy, crizotinib treatment resulted in a markedly higher objective response rate (OR = 6.86; 95% CI, 4.39-10.73; p < 0.00001). | Source → |
| Pregnant Lung Cancer Patient Treated with Crizotinib During Pregnancy | Lung Cancer | observational | — | Source → |
| Rare Eye Inflammation Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Crizotinib's Side Effects in Real-World Use | Lung Cancer | observational | — | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.